Disease · MONDO_0005298

osteoporosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. osteoporosis. Diseases, record MONDO_0005298. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005298

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: osteoporosis; Open Targets
Open Targets ID: MONDO_0005298; Open Targets
Other names: AGE RELAT OSTEOPOROSIS, Age Related Osteoporosis, Age-Related Bone Loss, Age-Related Bone Losses, Age-Related Osteoporoses, BONE LOSS AGE RELAT, Bone Loss, Age Related, Bone Losses, Age-Related, OSTEOPOROSIS AGE RELAT, Osteoporoses, Osteoporoses, Age-Related, Osteoporoses, Senile, Osteoporosis, Age Related, Osteoporosis, Post Traumatic, Osteoporosis, Senile, Post-Traumatic Osteoporoses, Post-Traumatic Osteoporosis, Senile Osteoporoses, Senile Osteoporosis, bone mineral density quantitative trait locus, osteoporosis, involutional, osteoporosis, postmenopausal; Open Targets
Disease Ontology: DOID:11476; Disease Ontology
MeSH: D010024; MeSH
NCI Thesaurus: C3298; NCI Thesaurus
Highest stage of its drugs: Approval, for 37 of its 117 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs117

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DENOSUMAB	CHEMBL1237023	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	105	88	87	Drugs and targets
TERIPARATIDE	CHEMBL525610	Protein	Approval	DailyMed, EMA Human Drugs and PMDA	99	83	83	Drugs and targets
ALENDRONIC ACID	CHEMBL870	Small molecule	Approval	TTD	60	59	56	Drugs and targets
ZOLEDRONIC ACID	CHEMBL4303669	Small molecule	Approval	DailyMed, EMA Human Drugs and PMDA	53	48	48	Drugs and targets
IBANDRONIC ACID	CHEMBL997	Small molecule	Approval	TTD	33	31	31	Drugs and targets
ROMOSOZUMAB	CHEMBL2107874	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	28	25	25	Drugs and targets
CHOLECALCIFEROL	CHEMBL1042	Small molecule	Approval	DailyMed	20	17	17	Drugs and targets
RALOXIFENE	CHEMBL81	Small molecule	Approval	TTD	18	17	16	Drugs and targets
ABALOPARATIDE	CHEMBL3301581	Protein	Approval	DailyMed, EMA Human Drugs and FDA	16	11	11	Drugs and targets
ALENDRONATE SODIUM	CHEMBL675	Small molecule	Approval	DailyMed, FDA and PMDA	39	10	10	Drugs and targets

1 to 10 of 117

See all 117 drugs

Targets34

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ESR1	Estrogen receptor	11	Estrogen receptor agonist; Estrogen receptor alpha agonist; Estrogen receptor alpha modulator; Estrogen receptor modulator	Approval	https://conductscience.org/library/genes/2099	Drugs and targets
FDPS	Farnesyl pyrophosphate synthase	10	Farnesyl diphosphate synthase inhibitor	Approval	https://conductscience.org/library/genes/2224	Drugs and targets
ESR2	Estrogen receptor	9	Estrogen receptor agonist; Estrogen receptor beta modulator; Estrogen receptor modulator	Approval	https://conductscience.org/library/genes/2100	Drugs and targets
SERPINC1	Antithrombin-III	7	Antithrombin-III activator	Unknown	https://conductscience.org/library/genes/462	Drugs and targets
VDR	Vitamin D3 receptor	6	Vitamin D receptor agonist	Approval	https://conductscience.org/library/genes/7421	Drugs and targets
PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	5	Parathyroid hormone receptor agonist	Approval	https://conductscience.org/library/genes/5745	Drugs and targets
AR	Androgen receptor	4	Androgen Receptor agonist; Androgen Receptor modulator	Approval	https://conductscience.org/library/genes/367	Drugs and targets
CALCR	Calcitonin receptor	3	Calcitonin receptor agonist	Approval	https://conductscience.org/library/genes/799	Drugs and targets
CTSK	Cathepsin K	3	Cathepsin K inhibitor	Phase 3	https://conductscience.org/library/genes/1513	Drugs and targets
PGR	Progesterone receptor	3	Progesterone receptor agonist	Approval	https://conductscience.org/library/genes/5241	Drugs and targets

1 to 10 of 34

See all 34 targets

Trials390

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 8 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04974723	Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women		22,054	2024-04-19	Osteoporosis, Postmenopausal	ABALOPARATIDE, TERIPARATIDE	Its record names the disease	ClinicalTrials.gov
NCT01416194	Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)		10,497	2020-05-18	Osteoporosis, Postmenopausal	BAZEDOXIFENE, RALOXIFENE	Its record names the disease	ClinicalTrials.gov
NCT00089791	A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis	Phase 3	7,808	2014-01-10	Osteoporosis	DENOSUMAB	Its record names the disease	ClinicalTrials.gov
NCT00205777	Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women	Phase 3	7,609	2013-04-10	Osteoporosis	BAZEDOXIFENE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT01575834	Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis	Phase 3	7,180	2018-11-08	Postmenopausal Osteoporosis	ROMOSOZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00525798	A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D	Phase 3	4,665	2012-10-18	Osteoporosis	CALCITONIN, SMC021	Its record names the disease	ClinicalTrials.gov
NCT00523341	Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis	Phase 3	4,550	2016-07-12	Osteopenia, Osteoporosis	DENOSUMAB	Its record names the disease	ClinicalTrials.gov
NCT01631214	Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis	Phase 3	4,093	2018-12-12	Postmenopausal Women With Osteoporosis	ALENDRONIC ACID, ROMOSOZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02089997	Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (Benet 75 mg Tablets) (12-month Treatment Survey)		3,304	2018-10-19	Osteoporosis	RISEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00145327	Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)	Phase 3	2,456	2011-04-20	Osteoporosis	ZOLEDRONIC ACID	Its record names the disease	ClinicalTrials.gov

1 to 10 of 390

See all 390 trials

Comparisons in its trials113

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Patients Treated With ABL vs Patients Treated With TPTD: Number of Participants With a Composite Endpoint of Nonfatal MI, Nonfatal Stroke, Heart Failure or In-hospital Cardiovascular Death	495 of 11,027	471 of 11,027	22,054	NCT04974723	Trial comparisons
Patients Treated With ABL vs Patients Treated With TPTD: Number of Participants With a Nonvertebral Fracture	313 of 11,027	333 of 11,027	22,054	NCT04974723	Trial comparisons
Patients Treated With ABL vs Patients Treated With TPTD: Number of Participants With Hip Fracture	112 of 11,027	125 of 11,027	22,054	NCT04974723	Trial comparisons
Patients Treated With ABL vs Patients Treated With TPTD: deaths from any cause	10 of 11,027	9 of 11,027	22,054	NCT04974723	Trial comparisons
Patients Treated With ABL vs Patients Treated With TPTD: Number of Participants With Composite Endpoint of Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or In-hospital Cardiovascular Death	221 of 11,027	211 of 11,027	22,054	NCT04974723	Trial comparisons
Denosumab 60 mg Q6M vs Placebo: Number of Participants With Nonvertebral Fractures	238 of 3,902	293 of 3,906	7,808	NCT00089791	Trial comparisons
Denosumab 60 mg Q6M vs Placebo: Number of Participants With a Hip Fracture	26 of 3,902	43 of 3,906	7,808	NCT00089791	Trial comparisons
Denosumab 60 mg Q6M vs Placebo: serious adverse events	1,004 of 3,886	972 of 3,876	7,762	NCT00089791	Trial comparisons
Denosumab 60 mg Q6M vs Placebo: Number of Participants With New Vertebral Fractures	86 of 3,702	264 of 3,691	7,393	NCT00089791	Trial comparisons
Placebo (Core+SE I+SE II) vs Bazedoxifene 20 mg (SE II): Number of Participants With Worsening Vertebral Fractures Through Month 84	1 of 1,741	7 of 3,410	5,151	NCT00205777	Trial comparisons

1 to 10 of 113

See all 113 comparisons in its trials

Papers from its trials234

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42282279	RESULT	1	PubMed
40057981	RESULT	1	PubMed
39933434	RESULT	1	PubMed
39527056	RESULT	1	PubMed
39485918	RESULT	1	PubMed
37948565	RESULT	1	PubMed
37798320	RESULT	1	PubMed
37574339	RESULT	1	PubMed
36602607	RESULT	1	PubMed
36382762	RESULT	1	PubMed

1 to 10 of 234

See all 234 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005298

GET https://conductscience.org/api/diseases/v1/MONDO_0005298/drugs?page=2

API reference For AI assistants